A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

August 1, 2029

Study Completion Date

August 1, 2029

Conditions

Advanced Malignant NeoplasmAdvanced or Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

IAP0971

Subjects receive IAP0971, which will be administered every 3 weeks in a 3-week cycle.

Trial Locations (1)

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

SUNHO（China）BioPharmaceutical CO., Ltd.

INDUSTRY